ebook img

Seminars in Liver Disease 2002: Vol 22 Index PDF

13 Pages·2002·3 MB·English
by  
Save to my drive
Quick download
Download
Most books are stored in the elastic cloud where traffic is expensive. For this reason, we have a limit on daily download.

Preview Seminars in Liver Disease 2002: Vol 22 Index

AUTHOR INDEX VOLUME 22, 2002 Agarwal, Shri Ram, 43 Kodonas, Fotis, 97 Alpini, Gianfranco, 227 Amitrano, Lucio, 83 Lai, Guan-Hua, 303 Arakawa, Masahiro, 73 Larrey, Dominique, 145 LaRusso, Nicholas F., 277 Balzano, Antonio, 83 Lazenby, Audrey J., 395 Bohan, Alan, 123 Leung, Nancy, $15 Boyer, James L., 123 LeSage, Gene, 227 Brancaccio, Vincenzo, 83 Liddle, Christopher, 109, 115 Brown, Steven John, 157 Lyra, Andre C., 103 Brunt, Elizabeth M., 103 Manns, Michael P., $7, 315, 339 Chen, Xian-Ming2,7 7 Marcellin, Patrick, $33 Chitturi, Shivakumar, 169 Marzioni, Marco, 227 Crawford, James M., 213 Masuzaki, Takao, 73 Czaja, Albert J., 365 McDonald, George B., 27 McFarlane, lan G., 317 DeLeve, Laurie D., 27 Min, Albert D., 207 Desmond, Paul Vincent, 157 Di Bisceglie, Adrian M., 103 Nenopoulou, Helen, 97 Doctor, R. Brian, 263 Neuberger, James, 379 Donaldson, Peter T., 353 Nishio, Akiyoshi, 291 Drevelegas, Antonios, 97 Ohbu, Makoto, 59 Endo, Kanenori, 303 Okuda, Kunio, 1, 15, 59, 73 Esteban, Rafael, $1 Okudaira, Masahiko, 59 Farrell, Geoftrey C., 109, 185 Papadimitriou, Constantine S., 97 Feranchak, Andrew P., 251 Phinizy,J o Lynne, 227 Ferrante, Dino, 395 Pincus, Steven, 103 Fitz,J . Gregory, 211, 241, 251 Fouassier, Laura, 263 Rose, Noel R., 387 Francis, Heather, 227 Sarin, Shiv K, 43 George, Jacob, 169 Sellers, Marty J., 395 Gershwin, M. Eric, 291 Shulman, Howard M., 27 Glaser, Shannon S., 227 Sirica, Alphonse E., 303 Goodwin, Bryan, 115 Sood, Gagan, 395 Guardascione, Maria A., 83 Stedman, Catherine, 195 Strassburg, Christian P., 339 Hytiroglou, Prodromos, 97 Suriawinata, Ariet, 207 loannidis, Ioannis, 97 Valla, Dominique-Charles, 5 lordanidis, Fotis, 97 van Leeuwen, Dirk J., 395 Jaeckel, Elmar, 325 Yoon, Byung-IL, 303 Kaplowitz, Neil, 137 Zhang, Zichen, 303 Keeffe, Emmet B., 291 Zoulim, Fabien, $23 Note: Numbers preceded by S indicate pages in Volume 22, Supplement Copyright © 2002 by Thieme Medical Publishers, Inc. , 333 Seventh Avenue, New York,N Y 10001, USA. Tel: +1(212) 5 SUBJECT INDEX VOLU22M, E20 02 A clinical criteria in, 145-155 Acarbose, hepatotoxicity of, 168-183 eliminating (negative), 145-155 N-Acetylcysteine, for sinusoidal obstruction syndrome, 27-41 positive, 145-155 N-Acetyltransferase 2, deficiency of, and drug-related method of, 145-155 hepatotoxicity, 145-155 performance of, 145-155 Acquired immunodeficiency syndrome (AIDS). See AIDS Age, and susceptibility to adverse hepatyiacti c Gdr ug reactions, cholangiopathy; Human immunodeficiency 145-155 virus (HIV) AIDS chol: ingiop: ithy Actin cytoskeleton etiology of, 277-289 and cell polarity, 263-276 pathogenesis of, cryptosporidiosis and, 277-289 in cholangiocyte disease, 263-276 Albendazole, hepatotoxicity of, 157-167 in cholangiocyte function, 263-276 Alcohol abuse, and drug-related hepatotoxicity, 145-155 functions of, in epithelial cells, 263-276 Aldosterone receptor antagonist, hepatotoxicity of, 168-183 ischemia and, 263-276 Aminoglycosides, hepatotoxicity of, 157-167 and membrane structure and tension, 263-276 Amiodarone, steatohepatitis caused by, 185-194 organization of, 263-276 Amodiaquine, hepatotoxicity of, 157-167 and transporter and channel activity, 263-276 Amoxicillin, hepatotoxicity of, 157-167 and vesicular trafficking, 263-276 Amphotericin B, hepatotoxicity of, 157-167 Acyclovir, hepatotoxicity of, 157-167 Ampicillin, hepatotoxicity of, 157-167 Adefovir dipivoxil Androstane receptor, constitutive. See Constitutive for chronic hepatitis B androstane receptor (CAR) in HBeAg-negative disease, $33-S36 Anemia, with idiopathic portal hypertension, 59-71 in HBeAg-positive disease, S33-S36 Angiotensin-converting enzyme (ACE) inhi bitors, lack of resistance to, $23-S31 hepatotoxicity of, 168-183 for lamivudine-resistant chronic hepatitis B Angiotensin II receptor inhibitors, hepatotoxicity of, 168-183 with compensated liver disease, S33-S36 Anorectal varices with decompensated liver disease before or after endoscopic obliteration of, 43-58 transplant, S33-S36 with extrahepatic portal vein obstruction, 43-a n x in HIV-coinfected patients, $33-S36 Antibiotics, hepatotoxicity of, 157-167 Adenosine receptors, 251-262 Anticoagulation Adenosine triphosphatase (ATPase), activity of, 251-262 with extrahepatic portal vein obstruction, 43-58 Adenosine triphosphate (ATP) for hepatic vein thrombosis, 5-14 as paracrine signaling molecule, 251-262 and herbal medicines, interactions of, 195-206 and purinergic regulation of cholangiocyte transport, in prevention of sinusoidal obstruction syndrome, 27-41 251-262 Anticonvulsants, hepatotoxicity of, 168-183 release Anti-cytosol antibodies type 1, in autoimmune hepatitis, ABC proteins and, 251-262 32932 9-351 cell volume and, 251-262 Antidepressants, hepatotoxicity of, 168-183 by cholangiocytes, 251-262 Antidiabetic agents, hepatotoxicity of, 168-183 by hepatocytes, 251-262 Antiepileptic agents, hepatotoxicity of, 168-183 kinase-dependent signaling pethways and, 251-262 Antifibrinolytic agents, for coagulation disorders, 83-96 regulation of, 251-262 Antifungal agents, hepatotoxicity of, 157-167 Adverse drug reactions Antihypertensive agents, hepatotoxicity of, 168-183 affecting liver. See a/so Hepatotoxicity, drug-related Antimicrobial agents, hepatotoxicity of, 157-167 antimicrobial agents and, 157-167 Antimitochondrial antibodies epidemiology of, 145-155 in autoimmune hepatitis, 395-405 susceptibility to, 145-155 in primary biliary cirrhosis, 291-302 causality assessment for Antineutrophil cytoplasmic antibody (ANCA), in chronological criteria in, 145-155 autoimmune hepatitis, 339-351 Note: Numbers preceded by S indicate pages in Volume 22, Supplement 1. Copyright © 2002 by Thieme Medical Publishers, Inc. , 333 Seventh Avenue, New York, NY 10001, USA. Tel: +1(212) 584-4662 1-4 SEMINARS IN LIVER DISEASE/VOLUME 22, NUMBER 4 2002 Antinuclear antibodies definition of, 317-324 in autoimmune hepatitis, 339-351 de novo, in transplant recipients, 365-377, 379-385 and overlapI syndromes, 339-35 diagg nosis of, 339-351, 395-405 in primary biliary cirrhosis, 339-351 experimental \ntiparasitic agents, hepatotoxicity of, 157-167 historical perspective on, 325-337 \ntiplatelet agents, and herbal medicines, interactions of, in mice, 325-337 195-206 in rabbits, 325-337 \ntipsychotics, hepatotoxicity of, 168-183 with fulminant hepatic failure, 395-405 (ntiretroviral therapy, hepatotoxicity of, 157-167 gene therapy for, 365-377 \nti-smooth muscle antibodies, in autoimmune hepatitis, genetic models of, 325-337 339-351 genetics of, 353-363 Antithrombin III, in prevention of sinusoidal obstruction advances in (future directions for), 353-363 syndrome, 27-41 histological features of, 317-324 \ntituberculosis agents, hepatotoxicity of, 157-167 historical perspective on, 317-324 Antiviral agents, hepatotoxicity of, 157-167 immunologic features of, 317-324 \poptosis liver graft dysfunction mimicking, 379-385 in cholangiocytes, 227-240 liver transplantation for, 365-377, 379-385, 395-405 defects in, and autoimmune disease, 387-394 allograft rejection in, 379-385 molecular machinery of, 137-144 chronic hepatitis after, 379-385 and necrosis, differentiation of, 137-144 contraindications to, 379-385 protection against, 137-144 immunosuppression after, 379-385, 395-405 in toxic liver injury, 137-144, 227-240 indications for, 379-385 \protinin, indications for, 83-96 timing of, 379-385 \sialoglycoprotein receptor, autoantibodies against, 339-351 nomenclature for, development of, 317-324 \spirin, hepatotoxicity of, 168-183 recurrence, post-transplant, diagnosis of, 379-385 \torvastatin, hepatotoxicity of, 168-183 relapse after remissanido dnru g withdrawal, \TP-binding cassette (ABC) proteins, 251-262 365-377 Itract) fera, hepatotoxicity of, 195-206 remission in, 365-377 Augmentin, hepatotoxicity of, 157-167 serological marker autoantibodies in, characterization of, Aut intibodic 339 351 itoimmune diseases, 387-394, 395-405 and severe cholestasis without inflammatory activity, liver immune hepatitis, 339-351, 395-405 transplantation for, 379-385 | ry biliary cirrhosis, 291-302, 395-405 treatment failure in, 365-377 \ut liver transplantation for, 379-385 { ‘ t ee l treatmento f, 365-377 ) tolerar I ns tor, 365-377 advances in future directions for , 365-377 tat t t t, therapeutic n children, 365-3 t 65 a citrhosis. 365=377 \ } S—A) comorbid \ditior ind, 365-377 \ut conventional schedules for, 365-377 394 } in elderly, 365-377 ' f ) evolving, 365-377 incomplete response to, 365-377 t n postmer iusal women, 365-377 4 pregnanc 365-37 4 suboptimal results of, management of, 365-377 | | 4 tvpe 1, 339 f $4 enetics t 5 63 \ | t \TH 15-31¢ Ove | tvpe 2, 339-351 : type 3. 339 . Autoimmunity ver t I 5/9-385 induction of, 387-394 itment ot, 365-3 mechanisms of, 38 394 | models of, 325-337 \zathioprine H ociated with autoimmune polyglandular syndrome, tor autoummune hepatitis, 365-377 microsomal autoantibodies in, 339-351 mechanismo f action of, 365-377 | utoantibodies in, 339-351 Azithromycin f roant vel I 339 351 cholestasis cause 20) 210 ; biochemical features of, 317-324 hepatotoxicity ot, 157-167 classification of, 317-324 Azole antifungals, hepatotoxicity of, 157-167 linical features of, 317-324 Aztreonam, hepatotoxicity of, 157--167 SUBJECT INDEX 1-5 B Carbenicillin, hepatotoxicity of, 157-167 Balloon occluded retrograde transvenous obliteration, for Cascara sagrada, hepatotoxicity of, 195-206 gastric varices, 1-3, 73-82 Caspases, in toxic liver injury, 137-144 Barbiturates, hepatotoxicity of, 168-183 Ceftriaxone, hepatotoxicity of, 157-167 Bentazepam, hepatotoxicity of, 168-183 Celecoxib Benzodiazepine, hepatotoxicity of, 168-183 hepatotoxicity of, 168-183 Beta blockers, hepatotoxicity of, 168-183 therapeutic potential in cholangiocarcinoma, 303-313 Bile Cell death. See also Necrosis formation of, 213-226, 251-262 initiation of, 137-144 mechanisms of, 241-249 mitochondria and, 137-144 secretion of programmed. See Apoptosis drug transporter function and, 123-136 Cell survival, mechanisms of, 137-144 regulation of, 241-249 Cell volume, hepatic and biliary, autocrine regulation of, Bile acids, metabolism of, regulation of, 115-122 251-262 Bile ducts, terminal, number of, 213-226 Cephalexin, hepatotoxicity of, 157-167 Bile ductules, 213-226 Cephalosporins, hepatotoxicity of, 157-167 Bile salt export pump (BSEP) Cerivastatin, hepatotoxicity of, 168-183 drug substrates for, 123-136 Chaparral leaf, hepatotoxicity of, 195-206 and hepatic drug uptake, 123-136 Chemotherapy, sinusoidal obstruction syndrome caused by, Biliary epithelium 27-41 diseases targeting, heterogeneity of, 227-240 Children, autoimmune hepatitis in, treatment of, 365-377 functional diversity of, 227-240 Chinese herbal medicines, hepatotoxicity of, 195-206 intrahepatic, functional heterogeneity of, 227-240 Chloramphenicol, hepatotoxicity of, 157-167 morphology of, 227-240 Chlorpromazine, hepatotoxicity of, 168-183 in primary biliary cirrhosis, 291-302 Chlorpropamide, hepatotoxicity of, 168-183 research on, advances in (future directions for), 227-240 Cholangiocarcinoma Biliary tree cyclooxygenase-2 in, 303-313 anatomy of, 213-226 ERBB-2 in, 303-313 extrahepatic, vascularization of, 227-240 pathogenesis of, animal models of, 303-313 intrahepatic risk factors for, 303-313 anatomy of, 227-240 therapeutic targeting in, 303-313 development of, 213-226 Cholangiocytes morphological heterogeneity of, 227-240 actin cytoskeleton in, 263-276 three-dimensional architecture of, 213-226 abipoolpotgoyt ico f,r es2p1o1n-s2e1s2 of, 227-240 vascularization of, 227-240 Biliopathy, portal Cl transport in, 241-249 wtirteha tmeexnttr ahoefp,a t4i3c- 58p ortal vein obstruction, 43-58 funecvtailouna tiilo nh etoefr, ogine nveiivtoy anofd. in2 vitro 4()t ools for, 227-240 Bosentan, and hepatic drug transport, 123-136 functions of, 227-240 Bromfenac, hepatotoxicity of, 168-183 large Budd-Chiari syndrome, 5-14. See a/so Hepatic vein, functional heterogeneity of, 227-240 thrombosis; Obliterative hepatocavopathy morphology of, 227-240 definition of, 15-26 proliferative respons¢ s of, ay 240 imaging in, 5-14 secretionb y pathophysiology of, 1-3, 5-14 cAMP-independent regulation of, 241-249 terminology for, 15-26 regulation of, 241-249 treatment of, graded approach to, 5-14 reseoan, radcvanhce s in (future directions for), 241-249 Budesonide, for autoimmune hepatitis, 365-377 vesicular trafficking of apical ti Bupropion, hepatotoxicity of, 168-183 241-249 re small functional heterogeneity of, 227-24 Calcium channel antagonists morphology otf, 227-240 hepatotoxicity of, 168-183 transport, purinergi signaling in, 241-249, 251-262 and steatohepatitis, 185-194 Cholangiopathy. See a/so AIDS chol hy Callilepsis laureola, hepatotoxicity of, 195-206 of large ducts, 227-240 Canals of Hering, 213-226 research on, advances in (future directions for), 227-240 Candesartan, hepatotoxicity of, 168-183 of small ducts, 227-240 Captopril, hepatotoxicity of, 168-183 Cholestasis Carbamazepine azithromycin-induced, 207-210 hepatotoxicity of, 168-183 drug-induced and steat hepatitis, 185-194 molecular mechanisms of, 123-136 SEMINARS IN LIVER DISEASE/VOLUME 22, NUMBER 4 2002 Cholestasis (continued CTLA-4, soluble, therapeutic applications of, 365-377 research on, advances in (future directions for), 123-136 CTLA4 gene, in autoimmune disease, 353-363 target transporterisn , 123-136 Cyclooxygenase (COX), COX-2 pure, 145-155 in cholangiocarcinoma, 303-313 Cirrhosis inhibitors, hepatotoxicity of, 168-183 hepatk Cyclophosphamide, sinusoidal obstruction syndrome caused and idiopathic portal hypertension, comparison of, by, 27-41 59-71 Cyclosporin A, and hepatic drug transport, 123-136 and treatment of autoimmune hepatitis, 365-377 Cyclosporine in surgical | patient, bleeding risk in, 83-96 for autoimmune hepatitis, 365-377 Cl ithromvcin n, hepatotoxicity of, 157-167 and herbal medicines, interactions of, 195-206 Cl idamycin, hepatotoxicity of, 157-167 Cystic fibrosis transmembrane conductance regulator, 123-136 \ lotiazepam, hepatotoxicity of, 168-183 as CAMP-regulated Cl channel, 241-249, 251-262 ( lotting factors. See Coagulation factors Cytarabine, hepatotoxicity of, 157-167 Cloxacillin, hepatotoxicity of, 157-167 Cytochrome P-450 Coagulation autoantibodies against, 339-351 inhibitors of, 83-96 CYP3A4 inducerands , herbal medicines, interactionosf , intrahepatic, sinusoidal obstruscyndtromie coausned by, 195-206 27-41 CYP2B gene, induction by phenobarbital, nuclear receptor CAR and, 115-122 clinical applications of, 83-96 CYP2C19, deficiency of, and drug-related hepatotoxicity, Coagulation cascade, 83-96 145-155 Coagulation disorders CYP2D6, deficiency of, and drug-related hepatotoxicity, with extrahepatic povreint obastrulctio n, 43-58 145-155 hepatic l involvCe ment in, 1-3, 83-96 CYP2D6 gene, mutation of, 185-194 nvasive pprr oceau;l:oer es ind Q2 96 gene expressi yn intation, 83-96 in liver, 115-122 nd pregnancy, 83-9 nuclear a PXR and, 115-122 in intracellular hepatic drug metabolism, 123-136 Cytokines in liver injury, animal models of, 325-337 Coagulation factor manipulations of, therapeutic +O of, 365-377 and sinusoidal obstruction syndron ne, 2/-41 in toxic liver injury, 137 144 £ 23-9 D Dapsone, hepatotoxicity of, 157-167 Detibrotide, for sinusoidal obstruction syndrome, 27-41 Deflazacort, for autoimmune hepatitis, 365-377 27-41 Desmopressin, for coagulation disorders, 83-96 Diabetes mellitus, d ug treatment of, hepatotoxicity of, 168 183 Diclofenac and hepatic drug transport, 123-136 tor autoimr ’ } 9 tit ae S hepatotoxicity of, 168 183 Dicloxacillin, hepatotoxicity of, 157-167 | teatohepatit 185 )4 Disease, and drug-related hepatotoxicity, 145-155 ; : | Uisseminated intravasc ular coagulation (DIC , in liver | lisease, 83-96 289 Doxycycline, hepatotoxicity of, 157-167 89 Drug-drug interactions and drug-related hepatotoxicity, 145-155 ri duced by, pathogenesis of, »772_7_79- 289 and 11 hepatic drug transport, Drug-herb interactions, 195-206 SY D1 gS. See al specific dru canalicular trat sport of, regulation of, 123-136 hepatic metabolism of nmune response t 7-289 initia an 113, 115-122 ot, hepatic transport of, mechanisms of, 123-136 89 and liver, 109-113 SUBJECT INDEX 1-7 reactive metabolites of, detoxification of, deficiency in, and angioarchitecture of, 73-82 drug-related hepatotoxicity, 145-155 bleeding site of, 73-82 Ductal plate system, development of, 213-226 cardiac, pathomorphology of, 73-82 Dysfibrinogenemia endoscopic obliteration ot, 43-58 clotting factor reduction in, 83-96 with extrahepatic portal vein obstruction, 43-58 in liver disease, 83-96 fundic balloon-occluded retrograde transvenous obliteration E for, 73-82 Elderly, autoimmune hepatitis in, treatment of, 365-377 endoscopic sclerotherapy for, 73-82 Emodin, therapeutic potential in cholangiocarcinoma, endoscopic variceal ligation for, 73-82 303-313 pathomorphology of, 73-82 Enalapril, hepatotoxicity of, 168-183 pathomorphology of, 1-3, 73-82 Endoplasmic reticulum (ER), antigens of, autoantibodies treatment of, 1-3 against, 339-351 Gemfibrozil, hepatotoxicity of, 168-183 Endothelin-1, in sinusoidal obstruction syndrome, 27-41 Gene expression, in toxic liver injury, 137-144 Epithelium, functional heterogeneity of, 227-240 Gene therapy, for autoimmune hepatitis, 365-377 Epsilon-aminocaproic acid, indications for, 83-96 Genetic analysis, in complex disease, 353-363 ERBB-2, in cholangiocarcinoma, 303-313 Germander, hepatotoxicity of, 195-206 Erythromycin esters, hepatotoxicity of, 157-167 Glibenclamide Erythromycin estolate, hepatotoxicity of, 157-167 and hepatic drug transport, 123-136 Esophageal varices hepatotoxicity of, 168-183 angioarchitecture of, 73-82 Gliclazide, hepatotoxicity of, 168-183 bleeding site of, 73-82 Glimepiride, hepatotoxicity of, 168-183 endoscopic injection sclerotherapy for, 73-82 Glipizide, hepatotoxicity of, 168-183 endoscopic obliteration of, 43-58 Glucosidase inhibitors, hepatotoxicity of, 168-183 endoscopic variceal ligation for, 73-82 Glutathione depletion, and hepatic drug tr insport; with extrahepatic portal vein obstruction, 43-58 123-136 pathomorphology of, 1-3, 73-82 Glutathione S-transferase (GST), type I, deficiency of, ana | posttreatment, pathology of, 73-82 drug-related hepatotoxicity, 145-14 55 treatment of, 1-3 Glutathione synthetase, deficiency of, and drug-related Esophagus, normal, angioarchitecture of, 73-82 hepatotoxicity, 145-155 Estrogens, and steatohepatitis, 185-194 Greater celandine, hepatotoxicity of, 195-206 Ethambutol, hepatotoxicity of, 157-167 Griseofulvin, hepatotoxicity of, 157-167 Etodolac, hepatotoxicity of, 168-183 Growth retardation, with extrahepatic portal vein obstruction, 43-58 F treatment of, 43-58 Factor VIla, recombinant, for coagulation disorders, 83-96 Fansidar, hepatotoxicity of, 157-167 H Fatty liver, of pregnancy, 83-96 I laloperidol, hepatotoxicity of, 168-183 Felbamate, hepatotoxicity of, 168-183 HELLP syndrome, 83-96 Fenofibrate, hepatotoxicity of, 168-183 Hemostasis, abnormalities of, in liver disease, 83-96 Fialuridine, hepatotoxicity of, 157-167 Heparin, in prevention of sinusoidal obstruction syndr Fibrates, hepatotoxicity of, 168-183 27-41 Fibrinolysis, in liver disease, 83-96 Hepatic vein Fibrinolytic system, 83-96 outflow block, 15-26 Flucloxacillin thrombosis, 1-3, 5-14 and hepatic drug transport, 123-136 causes of, 5-14 hepatotoxicity of, 157-167 clinical manifestations of, 5-14 Flucytosine, hepatotoxicity of, 157-167 diagnosis of, 5-14 Fluoxetine, hepatotoxicity of, 168-183 epidemiology of, 5-14 Fluvastatin, hepatotoxicity of, 168-183 histopathology of, 5-14 Fluvoxamine, hepatotoxicity of, 168-183 pathophysiology of, 5—14 Focal nodular hyperplasia, multiple, with malignancy, 97-102 prognosis for, 5-14 Foscarnet, hepatotoxicity of, 157-167 I Lepatic venous pressure gradient, in sinusoidal obstri Fosinopril, hepatotoxicity of, 168-183 syndrome, 27 4] Fresh-frozen plasma (FFP), for coagulation disorders, 83-96 Hepatitis Fusidic acid, hepatotoxicity of, 157-167 acute cholestatic, 145-155 autoimmune. See Autoimmune hepatitis (AIH G cryptogenic (seronegative), 395-405 Ganciclovir, hepatotoxicity of, 157-167 and treatment of autoimmune hepatitis, 365-3 Gastric vari drug-induced, diagnosis of, difficulties of, 145-155 1-8 SEMINARS IN LIVER DISEASE/VOLUME 22, NUMBER 4 2002 Hepatitis B] diagnosis of, 145-155 chron diagnostic criteria for, 145-155 epidemiology of, $1-S6 epidemiology of, 145-155 treatment of, advances in, $33-S36 advances in (future directions for), 145-155 HBe Ag negative genetic factors in, 145-155 adefovir dipivoxil for, $33-S36 incidence of, 145-155 lamivudine for, $15-S21 prevalence of, 145-155 susceptibility to, 145-155 HBe \g positive idefovir dipivoxil for, S33-S36 detection of, advances in (future directions for), lamivudine for, $15—-S21 145-155 HBeAg seroconversion in, $1-S6 terminology for, 145-155 management of, key issues in, $1-S6 drugs and, 109-113 treatment of. See a/so Interferon; Lamivudine occupational, 185-194 advances in, $33-S36 protection against duration of, and therapeutic effect, $1-S6 pitfalls in, 137-144 goals of, $1-S6 therapeutic possibilities for, 137-144 hepatotoxicity of, 15 7- 167 Herbal hepatotoxicity, 195-206 response to agents causing, 195-206 biochemical, $1-S6 diagnosis of, 195-206 clinical measures of, $1-S6 risk factors for, 195-206 detectioof,n $1-S6 and sinusoidal obstruction syndrome, 27-41 histological, $1—S6 Highly active antiretroviral therapy (HAART) monitorionf,g 51—-S6 hepatotoxicity of, 157-167 serological, $1 56 and steatohepatitis, 185-194 standardization of, need for, $1-S6 HMG-CoA reductase inhibitors, hepatotoxicity of, 168-183 time-based definitiofo,n $1-S6 Human immunodeficiency virus (HIV), antiretroviral virological, $1-S6 therapy for, hepatotoxicity of, 157-167 YMDD mutation in, $15 S21, $23-S31, $33-S36 Hydralazine, hepatotoxicity of, 168-183 HepatitB ivisru s (HBV Hypersplenism DNA, assays for, $1-S6 with extrahepatic portal vein obstruction, 43-58 drug resistance in, S23-S31 treatment of, 43-58 +7 > lecular mechanisms of, 523-531 with idiopathic portal hypertension, 59-71 aynamic nd kinetics of , > > errec 1cVveE pment of dru resistance, 523-$31 I >> —@ ttect o1 ea 923-931 Ibuprofen, hepatotoxicity of, 168-183 8323-831 Idoxuridine, hepatotoxicity of, 157-167 t side resistance, $23-S31 [mipenem, hepatotoxicity of, 157-167 Immune response §932-S 31 liver-specific, transgenic mice for study of, 325-337 $23-S31 in vertebrates, 387-394 } t. $23-S31 Immune response genes 1 492 S31 of MHC, 353-363 re C24 outside MHC, 353-363 11 ri \ Immune status, with extrahepatic portal vein obstruction, 339-35] le marré Immune system, genetic variations in, and drug-related t 1()3 10 hepatotoxicity, 145-155 Hey 1L D vodies 1n, 33> 9-35> ] Immunocyte activation, mechanisms of, 365-3 Hi HCC), in hepatB)i ,p treivesnt i Indomethacin, hepatotoxicity of, 168-183 ~ S13 Infections, and primary biliary cirrhosis, 291-302 Hepatoce \ e, 14{ 5-115655 Inferior vena cava Hepat tv. § membranous obstruction of, 15-26 ; tir hia thrombosis, 1-3,> 15-26 biochemic me clinical features f, 15-26 11.1 lial I diagnosis of, 15-26 lrug-re r .) epidemiology of, 15-26 K ( 14 ( etiology of, 15-26 lll l + twpes i pathophysiology of, 15-26 prognosis tor, 15-26 charact STIC cop treatment of, 15-26 vitl Infliximab, hepatotoxicity of, 168--183 SUBJECT INDEX i-9 Insulin, human, hepatotoxicity of, 168-183 Liver disease Insulin resistance syndrome, and nonalcoholic steatohepatitis, chronic, definition of, 145-155 185-194 drug-induced, diagnosis of, difficulties of, 145-155 Interferon, for hepatitis B, $1-S6, S7-S13 and drug-related hepatotoxicity, 145-155 efficacy versus tolerability of, S7-S13 Liver failure long-term outcomes with, $7-S13 after bone marrow transplantation, in patient with nonresponse to, predictors of, S7-S13 hepatitis C, 103-107 response to fulminant, in autoimmune hepatitis, 395-405 durability of, S7-S13 Liver injury predictors of, S7-S13 acute and slowed disease progression, $7-S13 cholestatic, 145-155 Irbesartan, hepatotoxicity of, 168-183 mixed pattern, 145-155 Isabgol, hepatotoxicity of, 195-206 cytokine models of, 325-337 Ischemia, effects on actin cytoskeleton, 263-276 drug-related Isoniazid, hepatotoxicity of, 157-167 definition of, 145-155 diagnostic criteria for, 145-155 Liver transplantation Jin Bu Huan, hepatotoxicity of, 195-206 for autoimmune hepatitis, 365-377, 379-385, 3 bleeding risk in, 83-96 K for Budd-Chiari syndrome, 5-14 K ava, hepatotoxicity of, 195-206 and lamivudine for hepatitis B, $15-S21 K idney, in sinusoidal obstruction syndrome, 27-41 for sinusoidal obstruction syndrome, 27-41 Losartan, hepatotoxicity of, 168-183 3 Lovastatin, hepatotoxicity of, 168-183 B -Lactam antibiotics, hepatotoxicity of, 157-167 L amivudine M for hepatitis B, S1-S6 Macrolides, hepatotoxicity of, 157-167 clinical experience with, $15-S21 Magnetic resonance imaging (MRI) guidelines for, $15-S21 of hepatic vein thrombosis, 5-14 in HBeAg-negative patients, $15-S21 of obliterative hepatocavopathy, 15-26 in HBeAg-positive patients, $15-S21 in sinusoidal obstruction syndrome, 27-41 HIV coinfection and, $15-S21 Ma-Huang, hepatotoxicity of, 195-206 primary end point for, $15-S21 Major histocompatibility complex (MHC) response to and clinical phenotype, 353-363 biochemical, $15-S21 disease encoded by, molecular models of, 353-363 durability of, $15-S21 in disease susceptibility and resistance, 353-363 serological, $15-S21 genes of, 353-363 virological, S1 5-S2 1 MDR1 gene, regulation of, by nuclear receptors PXR and safety of, $15-S21 CAR, 115-122 and transplantation, $15-S21 Mebendazole, hepatotoxicity of, 157-167 viral resistance to, $23-S31 Meloxicam, hepatotoxicity of, 168-183 hepatotoxicity of, 157-167 Membrane fluidity, and hepatic drug transport, 123-136 amotrigine, hepatotoxicity of, 168-183 Menopausal status, and treatment of autoimmune hepatitis, vaxatives, herbal, hepatotoxicity of, 195-206 365-377 .eflunomide, hepatotoxicity of, 168-183 6-Mercaptopurine, for autoimmune hepatitis, 365-377 selomyosarcoma, hepatic, high-grade, and multiple focal Meropenem, hepatotoxicity of, 157-167 nodular hyperplasia, 97-162 Metformin, hepatotoxicity of, 168-183 ipid-lowering agents, hepatotoxicity of, 168-183 Methotrexate, steatohepatitis caused by, 1 Aver Methyldopa biopsy of hepatotoxicity of, 168-183 bleeding risk in, 83-96 and steatohepatitis, 185-194 in sinusoidal obstruction syndrome, 27-41 Metronidazole, hepatotoxicity of, 157-167 cut surface of, with idiopathic portal hypertension, 59-71 Mice. See Transgenic mice development of, 213-226 Microarray technology, in research on drug transport and form of, with idiopathic portal hypertension, 59-71 toxicity, 123-136 histopathology of, with idiopathic portal hypertension, 59-71 Microsomal autoantibodies macroscopic findings in, with idiopathic portal in autoimmune hepatitis associated with autoimmune hypertension, 59-71 polyglandular syndrome, 339-351 size of, with idiopathic portal hypertension, 59-71 diseases associated with, 339-351 vascular changes of, with idiopathic portal hypertension, hepatitis C-associated, 339-351 hepatitis D-associated, 339-351 1-10 SEMINARS IN LIVER DISEASE/VOLUME 22, NUMBER 4 2002 patotoxicity of, 168-183 Organic cation transporter hepat ty of, 157-167 drug substrates for, 123-136 Mitochondria, in toxic liver injury, 137-144 and hepatic drug uptake, 123-136 Molecular footprint hypothesis, 353-363 Overlap syndromes, antinuclear antibodies and, 339-35 Monoamine oxidase inhibitors (MAOIs), hepatotoxicity of, Oxacillin, hepatotoxicity of, 157-167 Oxaprozin, hepatotoxicity of, 168-183 r receptors PXR and Oxidative stress, drug-related, in toxic liver injury, 137-144 g substr for, 123-136 P 1 hepatic drug uptake, 123-136 Paroxetine, hepatotoxicity of, 168-183 Multidrug resistance-1 P-glycoproteit Penicillins, hepatotoxicity of, 157-167 g ratest or, 123-136 Pennyroyal, hepatotoxicity of, 195-206 i hepatic drug uptake, 123-13¢ Pentamidine, hepatotoxicity of, 157-167 Multidrug resistant proteins, and hepatic drug uptake, 123-136 Pentoxifylline, and sinusoidal obstruction syndrome, 27-41 Mycophenolate mofetil, for 1utoimmune hepatitis, 365-377 Perhexiline maleate, steatohepatitis caused by, 185-194 Peribiliary glands, 213-226 utioning regimens s for, and prevention of sinusoida*l Peritoneovenous shunt, for sinusoidal obstruction syndrome, bstruction syndrome, 27-41 27-41 lal obstructic 17-41 Permissive gene pool, and autoimmune hepatitis, 353-363 My roliter c vein thrombosis Peroxisome proliferator activator receptor(s) (PPAR), and nonalcoholic steatohepatitis, 185-194 5 + Phenytoin, hepatotoxicity of, 168-183 N Pioglitazone, hepatotoxicity of, 168-183 Nafi 1 cit t. 157-167 Piroxicam, hepatotoxicity of, 168-183 Naproxet epatot tv ot, 168-183 Plant toxins, and sinusoidal obstruction syndrome, 27-41 Neer n toxic live yv, 137-144 Platelet disorders, in liver disease, 83-96 Netazodone, hepatotoxicity of, 168-183 Platelet transfusion, for coagulation disorders, 83-96 Niclotolan, hepatoto v of, 157-16 Portal biliopathy Nicotinic acid patotoxicity ot, 168-183 with extrahepatic portal vein obstruction, 43-58 N esulide epat yxicity of, 168-183 treatment of, 43-58 Nitrot toin, hepatotoxicity of, 157-167 Portal fibrosis, noncirrhotic, 1-3 N ucol Cc ste epati NASH Portal hypertension R \¢ 185 194 idiopathic, 1-3, 59-71 ] r d. 185-194 and cirrhosis, comparison of, 59-71 1 exp ire d. 185-194 clinical features of, 59-71 Nor le d lo erse criptas hibitors definition of, 59-71 patoto v of, 157-16 diagnostic criteria for, 59-71 N teroidal la v drugs (NSAIDs epidemiology of, 59-71 i hepa g trans] 123-136 etiologic considerations in, 59-71 if HA 183 hepatic veins in, 59-71 N re patot city « 57-16 histopathology of, 59-71 N ) t T pat ar liver pathology in, 59-71 morbid anatomy of, 59-71 N | S tase to portal fibrosis in, 59-71 i t 57 16 signs and symptoms of, 59-71 N | attine B. viral resistar A vascula3 r ch| anges in, 5e9w-e7 1 89 3-S3 noncirrhotic, 1-3, 43-58 Nucleot egrad d ptake pathwayfso r, 251-26 Portal vein obstruction, extrahepatic, 1-3, 43-58 N l \ verse hepatic drug in adults, etiology of, 43-58 145-155 animal models of, 43-58 in children, etiology of, 43-58 O clinical presentation of, 43-58 Obliterative hepat vopathy, 1-3, 15-26. § Interior diagnosis of, 43-58 ena Ca hromb« S etiolofo, g43y-5 8 Olanzapine epatotoxicity of, 168-183 hemodynamic studies in, 43-58 Or anion transporting polypeptide-2 (Oatp2 hepatic functional status with, 43-58 regulationb y PXR, 115-122 hypercoagulable states and, 43-58 Organic anion transporting polypeptides OATP/Oatp pathology of, 43-58 drug substrates tor, 123-13¢ pathophysiology of, 43-58 and hepatic ar pharmacotherapy in, 43-58

See more

The list of books you might like

Most books are stored in the elastic cloud where traffic is expensive. For this reason, we have a limit on daily download.